Pharma Digest

Generic pricing & supply intelligence · updated daily 6am CT · latest Oct 15, 2026

Generics

Cardinal Health and McKesson both extend their CVS distribution deals to June 2032

Pharmaceutical Commerce • Oct 2, 2026

Locking up CVS — about 28% of Cardinal's revenue and a top McKesson account — through 2032 removes the largest re-bid risk hanging over two of the Big Three; Cardinal's is a binding LOI (current scope intact) while McKesson's is still an agreement in principle, and the renewal keeps the branded-and-generic volume that clears through these chains inside the incumbent sourcing networks rather than up for contest.

Beneath a calm surface, Wall Street sees real trouble stirring for biotech

STAT News • Oct 15

Deepening investor angst below the biotech tape points to more capital selectivity at the innovative end — the funding environment that ultimately decides which pipelines reach the cliffs a distributor plans around, no near-term generic read.

Generics

Par Health pulls 22 lots of argatroban injection over particulate — the go-to HIT anticoagulant, at the hospital level

FDA • Oct 13

A large-volume pull of the IV direct thrombin inhibitor relied on for heparin-induced thrombocytopenia tightens a multi-source but critical-care injectable base — and marks Par Health's third sterile-injectable recall on the board.

Generics

Trump administration delays by 90 days the rule that would curb imported medicines from Canada and overseas

STAT News • Oct 14

The personal-import crackdown we've tracked flips from imminent to pushed back three months — a reprieve that keeps the licensed-international-pharmacy lane some cheaper generics reach U.S. patients through open for now.

Generics

Drug Channels lays out its 10 crucial trends facing U.S. drug wholesalers in 2026 and beyond

Drug Channels • Oct 14

Adam Fein's annual read on the Big Three distributors — consolidation, pricing realignment and shifting channel economics — maps directly onto where the generic and specialty volume a distributor sources actually clears.

Generics

Three former FDA chiefs call the DOGE cuts "one of the biggest disasters in American history"

STAT News • Oct 14

Lost institutional capacity at the FDA is the same bottleneck that paces generic and biosimilar approvals — and the foreign-inspection and import-alert enforcement a distributor's buy-side leans on.